Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharma firm Glialogix has entered into a Sponsored Research Agreement with Fast Forward, a nonprofit organization established by the National Multiple Sclerosis (MS) Society to accelerate the development of treatments for multiple sclerosis (MS).
Subscribe to our email newsletter
Under the deal, Fast Forward will provide funding to Glialogix for preclinical studies of GLX1112, a first-in-class neuroprotective therapy designed to slow the accumulation of disability in progressive MS.
Key priority of the National MS Society’s research campaign is to support the research and development of therapies that reduce the accumulation of disability in progressive MS and restore neuronal function.
Glialogix chief executive officer Mark Moore said: "The majority of MS disability occurs in the progressive forms of MS, but drugs that are effective for relapsing MS have shown limited to no efficacy in progressive MS.
"The research funding from Fast Forward validates our therapeutic approach for GLX1112 and will help us advance this investigational drug as a potential breakthrough therapy for the treatment of patients with progressive MS."
Fast Forward will fund the research which will include advanced pharmacokinetic testing, preclinical models and further mechanistic trials of GLX1112.
Glialogix chief scientific officer and and investigator of the GLX1112 preclinical research Thadd Reeder said a unique aspect of the company’s program is that the active pharmaceutical ingredient in GLX1112 has already showed a promising efficacy signal in progressive MS patients.
"The support of Fast Forward will enable us to build on that signal by moving GLX1112 closer to clinical trials and may contribute to the development of new clinical trial designs in progressive MS," Reeder said.